APOA1 and acute coronary syndrome: Final conclusions can be drawn following the results of an ongoing multicenter phase 3 study to evaluate the efficacy and safety of CSL112 (new formulation of apoA-I reconstituted with phosphatidylcholine) on reducing the risk of major adverse cardiovascular events in subjects with acute coronary syndrome.